AstraZeneca PLC (AZN) Stock: Price, Forecast & Analyst Target
AstraZeneca PLC (AZN) — MoonshotScore 85/100 (Exceptional band), calculated Oct 5, 2026. Price $156.90 (-0.51%), as of the Oct 2, 2026 trading session; market cap $243B. Expected results Oct 30, 2026.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 48.97× (market value Oct 2, 2026; cash Jun 30, 2026) · expected results Oct 30, 2026
AstraZeneca PLC · AZN · NYSE · Healthcare · Drug Manufacturers - General
Research dated 2026-09-12: AstraZeneca discovers, develops, manufactures and commercializes prescription medicines, with oncology, cardiovascular, renal, metabolic and rare-disease franchises carrying the business today. Its case depends on whether expanding medicine sales can keep outrunning heavy pipeline spending while preserving cash generation and containing leverage.
Price as of Oct 2, 2026
Key Statistics
MoonshotScore v2 · AstraZeneca (AZN)
ExceptionalWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Elite quality and elite growth, though the balance sheet is only decent. Business Quality: Elite; Financial Safety: Sound; Valuation: Full; Growth Durability: Compounding; Momentum: Quiet.
- quarterly revenue $15.38B (Q2 FY2026, quarter ended Jun 2026)
- EPS beat 6 of 8
- Altman Z 3.29 · Piotroski F 8
Helping: business quality, durable growth
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 86 | Exceptional | |
| 86 | Exceptional | |
| 86 | Exceptional | |
| 86 | Exceptional | |
| 86 | Exceptional | |
| 86 | Exceptional |
The score was 85 in the stored Oct 4, 2026 snapshot and remains 85 in the current publication computed Oct 5, 2026 (0); the largest pillar moves were Growth Durability -1; the pillar moves offset under the sector-relative weighting, so the headline score is unchanged. This current publication is not yet represented in the immutable snapshot archive.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $156.90 | |
| Change on the day | -0.51% | |
| 52-week range | $153.41 – $212.71 | |
| Market capitalisation | $243B | |
| Price / earnings (trailing) | 23.34 | |
| Shares traded on the day | 2.64M | |
| Beta (volatility vs the S&P 500) | 0.21 | |
| Dividends per share (last 12 months) | $3.23 | |
| Dividend yield (last 12 months) | 2.06% |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings call · management outlook
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
Management outlook
Core R&D represented 23% of total revenue in the first half, and we continue to expect R&D expenses to be at the upper end of the low 20s percentage range for the full year as we continue to build our pipeline for long-term growth opportunities, including bispecifics, cell therapies, T-cell engagers in addition to our CVRM portfolio.
Aradhana Sarin · Statement from
We are reiterating our outlook for the full year. We expect total revenue to increase by a mid- to high single-digit percentage and core EPS to increase by low double-digit percentage at constant exchange rates.
Aradhana Sarin · Statement from
Statement dates identify the earnings call, not a deadline. Management expectations and provider estimates can change.
Read management statementsCouncil Score · weighted blend of 2 available disciplines
Council score for AstraZeneca (AZN): Bullish Lean
71/100 · ASome lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
5 lenses, 5 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Oct 5, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
One of these lenses reads this company less favourably than the MoonshotScore does: Englander-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
On Sep 9, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 5, 2026, except a card that shows its own read date.
Watch the AZN film — every key number, told as a short cinematic story
~2 min · open the film
What is AstraZeneca (AZN), and what does it report?
Short answer · as of
AstraZeneca is an integrated global biopharmaceutical company, not a development-stage biotech awaiting a flagship approval. It sells established prescription medicines through primary and specialty care channels while funding discovery, clinical development, manufacturing and commercialization across a broad geographic network.
Research dated 2026-09-12.
AstraZeneca is an integrated global biopharmaceutical company, not a development-stage biotech awaiting a flagship approval. It sells established prescription medicines through primary and specialty care channels while funding discovery, clinical development, manufacturing and commercialization across a broad geographic network.
The reporting mixes therapeutic-area totals with named medicine sales: oncology and rare disease appear alongside Tagrisso and Farxiga, while cardiovascular, renal and metabolic medicine revenue is also grouped as a franchise. Those lines describe the portfolio from different angles and should not be treated as mutually exclusive components.
What do the latest results show for AstraZeneca (AZN)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $15.38B.
Research dated 2026-09-12.
Revenue edged higher in the latest reported period, and gross profit also advanced, but operating profit, net income and earnings per share retreated as research and commercial spending rose. Reported earnings exceeded expectations while revenue came in slightly below expectations, breaking the recent run of revenue outperformance without erasing the broader annual growth trend.
Management reiterated its constant-currency growth outlook and continues to direct an elevated share of revenue toward research spanning oncology technologies and the cardiovascular, renal and metabolic pipeline. It also expects product mix to pressure gross margin as seasonal demand shifts toward lower-margin FluMist and Beyfortus, making the revenue mix as important as the revenue direction.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · revenue
- $15.38B Jun 30, 2026
- Latest quarter · R&D
- $4.05B Jun 30, 2026
- Latest quarter · SG&A
- $5.80B Jun 30, 2026
- Latest quarter · FMP standardized operating result
- $3.16B Jun 30, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Jun 30, 2026 | $15.38B | $4.05B | $5.80B | $3.16B |
| Mar 31, 2026 | $15.29B | $3.49B | $5.06B | $4.25B |
| Dec 31, 2025 | $15.50B | $3.86B | $5.64B | $2.98B |
| Sep 30, 2025 | $15.19B | $3.66B | $5.23B | $3.58B |
USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $15.38B Jul 27, 2026
- Latest report · revenue estimate
- $15.44B Jul 27, 2026
- Latest report · revenue vs estimate
- Below estimate Jul 27, 2026
- Latest report · EPS vs estimate
- Above estimate Jul 27, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Jul 27, 2026 | $15.38B | $15.44B | $2.6300 | $2.5000 |
| Apr 29, 2026 | $15.29B | $14.93B | $2.5800 | $2.5700 |
| Feb 10, 2026 | $15.50B | $15.44B | $2.1200 | $2.0900 |
| Nov 6, 2025 | $15.19B | $14.78B | $2.3800 | $2.2800 |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $15.38B | $2.51B | $1.59 (diluted) |
| Q1 FY2026 | $15.29B | $3.08B | $1.97 (diluted) |
| Q4 FY2025 | $15.50B | $2.33B | $1.48 (diluted) |
| Q3 FY2025 | $15.19B | $2.53B | $1.62 (diluted) |
What are the financial strengths and risks for AstraZeneca (AZN)?
Short answer
Cash and short-term investments were $4.96B at the Jun 30, 2026 balance-sheet date. Operating cash flow was $2.89B for the quarter ended Jun 30, 2026, meaning operations generated cash. These figures do not establish a cash runway.
Research dated 2026-09-12.
Operating cash flow has remained positive throughout the displayed history despite substantial capital expenditure and rising research investment. Profitability screens remain healthy, but the latest cash balance declined from the preceding period and near-term liquidity ratios indicate that liquid current resources do not fully cover current obligations.
Debt materially exceeds cash and short-term investments, and it remains larger even when long-term investment holdings are included. AstraZeneca therefore needs its marketed portfolio to keep funding pipeline investment and capital needs; weaker sales from major franchises, heavier commercialization expense or the expected unfavorable product mix would reduce the room available for debt service and reinvestment.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- $2.89B Jun 30, 2026
- Previous quarter · operating cash flow
- $3.36B Mar 31, 2026
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Jun 30, 2026 | $2.89B | −$752.85M |
| Mar 31, 2026 | $3.36B | −$1.54B |
| Dec 31, 2025 | $2.43B | −$1.05B |
| Sep 30, 2025 | $5.13B | −$1.73B |
Operating cash-flow bars share one scale and show magnitude; negative values mean cash used.
USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway.
What should you watch next at AstraZeneca (AZN)?
Short answer · as of
The next earnings report is expected on Oct 30, 2026.
Research dated 2026-09-12.
The upcoming report should be read through product mix rather than revenue alone. Watch whether overall sales maintain momentum, whether earnings growth holds as research and commercial costs rise, and whether the anticipated FluMist and Beyfortus mix change produces the gross-margin pressure management described.
Cash conversion is the financial cross-check: operating cash flow should remain sufficient after capital spending while cash, investments and debt stay in balance. Tagrisso, Farxiga, the broader oncology franchise and rare disease sales deserve particular attention because their scale makes them central to whether commercial growth can absorb sustained pipeline investment.
What management is planning
Management expectations, not completed milestones or guarantees. Selected verbatim excerpts; dates follow the transcript provider.
Core R&D represented 23% of total revenue in the first half, and we continue to expect R&D expenses to be at the upper end of the low 20s percentage range for the full year as we continue to build our pipeline for long-term growth opportunities, including bispecifics, cell therapies, T-cell engagers in addition to our CVRM portfolio.
Aradhana Sarin ·
We are reiterating our outlook for the full year. We expect total revenue to increase by a mid- to high single-digit percentage and core EPS to increase by low double-digit percentage at constant exchange rates.
Aradhana Sarin ·
While the margin improved in the second quarter compared to the first quarter, we expect lower gross margin in the second half, consistent with prior years, reflecting seasonal demand patterns for lower-margin medicines such as FluMist and Beyfortus.
Aradhana Sarin ·
Other operating income was $341 million in the first 6 months, consisting of royalties and small regional divestitures, and we anticipate a broadly similar level in the second half.
Aradhana Sarin ·
How does AstraZeneca compare with its peers?
Short answer
AstraZeneca's score ranks 5th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-12.
AstraZeneca combines the commercial reach of a global drug manufacturer with research spending more commonly associated with an aggressively expanding pipeline. Unlike a biotech whose value rests mainly on future approvals, AstraZeneca already draws substantial sales from oncology, cardiovascular, renal, metabolic and rare-disease medicines while developing new modalities through internal work and collaborations.
Oncology is the largest disclosed therapeutic grouping, but the business is not an oncology pure play: Farxiga, the wider cardiovascular, renal and metabolic franchise, and rare disease provide meaningful commercial breadth. That mix spreads demand across established medicines and treatment areas, while retaining exposure to the research cost and execution risk inherent in bringing new therapies to market.
| Company | Price | Market value | Score |
|---|---|---|---|
| $1142.85 Oct 2, 2026 | $1.08T | 97 5-pillar Oct 5, 2026 | |
| $61.15 Oct 2, 2026 | $125B | 92 5-pillar Oct 5, 2026 | |
| $256.03 Oct 2, 2026 | $617B | 90 5-pillar Oct 5, 2026 | |
| $47.03 Oct 2, 2026 | $94.2B | 88 5-pillar Oct 5, 2026 | |
| AstraZeneca (AZN) — this page | $156.90 | $243B | 85 |
| $141.00 Oct 2, 2026 | $268B | 84 5-pillar Oct 5, 2026 | |
| $403.04 Oct 2, 2026 | $218B | 84 5-pillar Oct 5, 2026 | |
| $39.92 Oct 2, 2026 | $95.9B | 83 5-pillar Oct 5, 2026 | |
| $262.82 Oct 2, 2026 | $464B | 78 5-pillar Oct 5, 2026 | |
| $144.30 Oct 2, 2026 | $356B | 75 5-pillar Oct 5, 2026 | |
| $27.80 Oct 2, 2026 | $158B | 68 5-pillar Oct 5, 2026 | |
| $219.88 Oct 2, 2026 | $32.5B | 67 5-pillar Oct 5, 2026 | |
| $7.31 Oct 2, 2026 | $6.18B | 66 5-pillar Oct 5, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $158.00 – $216.00
- Consensus target
- $186.67
- Median target
- $185.00
Consensus record · Captured .
Measured against a quoted price of $156.90 (as of Oct 2, 2026).
Insider activity
Form 4 records via FMP · Of the newest 60 records, those within the last 180 days, newest dated Sep 8, 2026
- Transactions
- 7
- Identified insiders
- 1
- Purchases
- 1
- Sales
- 1
- Other transactions
- 5
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
- Institutional ownership
- 52.0% Period end Jun 30, 2026
- Previous quarter · ownership
- 48.8% Prior to period end Jun 30, 2026
- Reporting holders
- 1,523 Period end Jun 30, 2026
- Previous quarter · holders
- 1,371 Prior to period end Jun 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Investor Ab | 51,587,810 |
| Vanguard Capital Management LLC | 45,386,190 |
| Capital International Investors | 34,576,070 |
| Norges Bank | 33,864,172 |
| Capital World Investors | 30,075,134 |
Quarterly filings lag the period end. Holder rows are names in the provider snapshot, not a verified ranking; individual filing dates are not supplied. Related managers may appear separately, so these positions are not summed. Holder snapshot as of Jun 30, 2026.
What has been published about AstraZeneca (AZN)?
- Summit Therapeutics Secures $2 Billion Investment From AstraZeneca
- Summit Therapeutics Announces Closing Of AstraZeneca's $2B Convertible Preferred Investment, Equivalent To $18.36/Share Of Common Stock
- AstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics
- Biofrontera (NASDAQ:BFRI) & Astrazeneca (NYSE:AZN) Critical Contrast
AstraZeneca Healthcare Stock: Key Questions Answered
Research dated 2026-09-12; the answers below are from that research, and the full attribution is under Sources. The last 3 questions are answered from this page's own dated data, not from the research.
How do Tagrisso and Farxiga fit into AstraZeneca’s reported revenue?
Tagrisso and Farxiga are named medicine sales presented alongside broader therapeutic-area totals. Adding every displayed line together would overstate revenue because the presentation describes overlapping portfolio views rather than independent segments.
Why can AstraZeneca’s gross margin weaken while revenue grows?
Management expects seasonal demand for lower-margin FluMist and Beyfortus to weigh on product mix. Revenue can therefore advance while the profit retained from each unit of sales declines.
Can AstraZeneca fund its pipeline from operating cash flow?
Operating cash flow has stayed positive across the displayed periods while research spending remained elevated, although capital expenditure absorbs a meaningful portion. The durability of that funding model depends on marketed medicines continuing to support pipeline and infrastructure investment.
Is AstraZeneca mainly an oncology company?
Oncology is its largest disclosed therapeutic grouping, led in part by Tagrisso, but AstraZeneca also has substantial cardiovascular, renal, metabolic and rare-disease businesses. Farxiga and the rare-disease portfolio make the company broader than an oncology pure play.
What is the AZN stock price today?
The last price recorded on this page for AstraZeneca PLC (AZN) is $156.90, as of the Oct 2, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the AZN price target?
The analyst consensus price target for AstraZeneca PLC (AZN) is $186.67 (range $158.00 to $216.00, median $185.00), per FMP data captured Oct 5, 2026. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Does AZN pay a dividend?
Yes. AstraZeneca PLC (AZN) shows a trailing 12-month dividend yield of 2.06%, as of Oct 2, 2026, in the data on this page. Payout ratio and cash-flow coverage decide whether it can last, and past dividends do not guarantee future payments.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are shown with each answer. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (85 figures)
The 85 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
OFFICIAL — 2 facts from SEC filings and earnings calls
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
prod.outlook | Management outlook — call excerpts | Aradhana Sarin (Jul 27, 2026): Core R&D represented 23% of total revenue in the first half, and we continue to expect R&D expenses to be at the upper end of the low 20s percentage range for the full year as we continue to build our pipeline for long-term growth opportunities, including bispecifics, cell therapies, T-cell engagers in addition to our CVRM portfolio. Aradhana Sarin (Jul 27, 2026): We are reiterating our outlook for the full year. We expect total revenue to increase by a mid- to high single-digit percentage and core EPS to increase by low double-digit percentage at constant exchange rates. Aradhana Sarin (Jul 27, 2026): While the margin improved in the second quarter compared to the first quarter, we expect lower gross margin in the second half, consistent with prior years, reflecting seasonal demand patterns for lower-margin medicines such as FluMist and Beyfortus. Aradhana Sarin (Jul 27, 2026): Other operating income was $341 million in the first 6 months, consisting of royalties and small regional divestitures, and we anticipate a broadly similar level in the second half. | OFFICIAL | Company earnings call, transcript via Financial Modeling Prep (FMP) — Selected verbatim statements from the latest available call, dated by the transcript provider. Management expectations, not completed milestones or guarantees. Relative dates retain the speaker's wording. | |
id.hq | SEC filing business address | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA | OFFICIAL | SEC EDGAR filer business address — The SEC filer business address. Our market-data provider separately lists "1 Francis Crick Avenue, Cambridge, CA, CB2 0AA, GB". |
FMP — 73 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.next | Next earnings date | Oct 30, 2026 | FMP | Financial Modeling Prep (FMP) earnings calendar — The date is our provider's estimate until the company confirms it. | |
px.last | Latest provided price | $156.90 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-04T20:54:41.943Z. | |
px.change | Change on the day | -0.51% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $243B | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-02. FMP quote timestamp: 2026-10-02T20:00:02.000Z. Captured from FMP at 2026-10-04T20:54:40.897Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | −$0.80 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q2 FY2026 | $15.38B | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
px.pe | Price / earnings (trailing) | 23.34 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 2.64M | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 0.21 | FMP | Financial Modeling Prep (FMP) company profile | |
id.ceo | Chief executive | Pascal Claude Roland Soriot | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
id.employees | Employees | 96,100 | FMP | Financial Modeling Prep (FMP) employee count, from the company's filing | |
fin.annual | Revenue and net result by fiscal year | 5 fiscal years, FY2021 through FY2025: FY2021 revenue $37.42B, net result $112.00M; FY2022 revenue $44.35B, net result $3.29B; FY2023 revenue $45.81B, net result $5.96B; FY2024 revenue $54.07B, net result $7.04B; FY2025 revenue $58.74B, net result $10.26B | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements | |
fin.rev_mix | Reported revenue segments | CVRM $12.76B · Farxiga $8.40B · Tagrisso $7.25B · Rare Disease $9.13B · Total Oncology $23.70B | FMP | Financial Modeling Prep (FMP) revenue segmentation, from the company's 10-K | |
fin.gross_margin | Gross margin (trailing twelve months) | 79.3% | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.q_table.depth.2026-06-30.revenue_k | Revenue — period end 2026-06-30 | $15.38B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.rd_k | R&D — period end 2026-06-30 | $4.05B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.sga_k | SG&A — period end 2026-06-30 | $5.80B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.operating_result_k | FMP standardized operating result — period end 2026-06-30 | $3.16B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.revenue_k | Revenue — period end 2026-03-31 | $15.29B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.rd_k | R&D — period end 2026-03-31 | $3.49B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.sga_k | SG&A — period end 2026-03-31 | $5.06B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.operating_result_k | FMP standardized operating result — period end 2026-03-31 | $4.25B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.revenue_k | Revenue — period end 2025-12-31 | $15.50B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.rd_k | R&D — period end 2025-12-31 | $3.86B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.sga_k | SG&A — period end 2025-12-31 | $5.64B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.operating_result_k | FMP standardized operating result — period end 2025-12-31 | $2.98B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.revenue_k | Revenue — period end 2025-09-30 | $15.19B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.rd_k | R&D — period end 2025-09-30 | $3.66B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.sga_k | SG&A — period end 2025-09-30 | $5.23B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.operating_result_k | FMP standardized operating result — period end 2025-09-30 | $3.58B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
earn.history.depth.2026-07-27.revenue_actual | Revenue · reported — report date 2026-07-27 | $15.38B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-07-27.revenue_estimated | Revenue · estimate — report date 2026-07-27 | $15.44B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-07-27.eps_actual | EPS · reported — report date 2026-07-27 | $2.6300 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-07-27.eps_estimated | EPS · estimate — report date 2026-07-27 | $2.5000 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-04-29.revenue_actual | Revenue · reported — report date 2026-04-29 | $15.29B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-04-29.revenue_estimated | Revenue · estimate — report date 2026-04-29 | $14.93B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-04-29.eps_actual | EPS · reported — report date 2026-04-29 | $2.5800 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-04-29.eps_estimated | EPS · estimate — report date 2026-04-29 | $2.5700 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-10.revenue_actual | Revenue · reported — report date 2026-02-10 | $15.50B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-10.revenue_estimated | Revenue · estimate — report date 2026-02-10 | $15.44B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-10.eps_actual | EPS · reported — report date 2026-02-10 | $2.1200 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-10.eps_estimated | EPS · estimate — report date 2026-02-10 | $2.0900 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-06.revenue_actual | Revenue · reported — report date 2025-11-06 | $15.19B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-06.revenue_estimated | Revenue · estimate — report date 2025-11-06 | $14.78B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-06.eps_actual | EPS · reported — report date 2025-11-06 | $2.3800 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-06.eps_estimated | EPS · estimate — report date 2025-11-06 | $2.2800 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
fin.cash_investments | Cash and short-term investments | $4.96B | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. | |
fin.opcf_latest | Latest-quarter operating cash flow | $2.89B | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Period end: 2026-06-30. Negative operating cash flow means cash used. This figure is not a cash-runway estimate. | |
fin.long_term_investments | Long-term investments (classification unverified) | $4.66B | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.total_debt | Total debt | $32.20B | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.price_to_book | Price to book value | 4.82× | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.opcf.depth.2026-06-30.operating_cash_flow_m | Operating cash flow — period end 2026-06-30 | $2.89B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-03-31.operating_cash_flow_m | Operating cash flow — period end 2026-03-31 | $3.36B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-06-30.capex_m | Capital expenditure (reported) — period end 2026-06-30 | −$752.85M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-03-31.capex_m | Capital expenditure (reported) — period end 2026-03-31 | −$1.54B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.operating_cash_flow_m | Operating cash flow — period end 2025-12-31 | $2.43B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.capex_m | Capital expenditure (reported) — period end 2025-12-31 | −$1.05B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-09-30.operating_cash_flow_m | Operating cash flow — period end 2025-09-30 | $5.13B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-09-30.capex_m | Capital expenditure (reported) — period end 2025-09-30 | −$1.73B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
earn.pt_range | Analyst price target, low to high | $158.00 – $216.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
earn.pt_consensus | Consensus analyst price target | $186.67 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
earn.pt_median | Median analyst price target | $185.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
own.insiders | Insider transactions via FMP | 7 transactions · 1 purchases, 1 sales, 5 other transactions · 1 identified insiders · of the newest 60 records, those within the last 180 days, newest dated Sep 8, 2026 | FMP | Financial Modeling Prep (FMP), carrying Form 4 transaction records — Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent. | |
own.institutions.depth.ownership_pct | Institutional ownership | 52.0% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.ownership_pct_previous_quarter | Previous quarter · ownership | 48.8% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.institutions.depth.holders | Reporting holders | 1,523 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.holders_previous_quarter | Previous quarter · holders | 1,371 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.top_holders.depth.holder_0.shares | Investor Ab — shares in provider snapshot | 51,587,810 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_1.shares | Vanguard Capital Management LLC — shares in provider snapshot | 45,386,190 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_2.shares | Capital International Investors — shares in provider snapshot | 34,576,070 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_3.shares | Norges Bank — shares in provider snapshot | 33,864,172 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_4.shares | Capital World Investors — shares in provider snapshot | 30,075,134 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. |
UNRECORDED — 3 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.history | Reported versus estimated, recent quarters | EPS beat 6 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-10-03 | |
fin.scores | Distress and quality screens | Altman Z 3.29 · Piotroski F 8 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-04 · Expired observation | |
px.range52 | 52-week range | $153.41 – $212.71 | UNRECORDED | Stored company-profile observation — Captured 2026-10-03 |
COMPUTED — 5 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
fin.mcap_to_cash | Market value per dollar of cash and short-term investments | 48.97× | — | COMPUTED | Computed on this page from the figures above — The market capitalisation printed on this page divided by cash and short-term investments of $4.96B at Jun 30, 2026. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. Market cap record date: 2026-10-02. Balance-sheet reference date: 2026-06-30. The inputs do not establish a single common source date for this ratio. |
div.ttm_per_share | Dividends per share, last 12 months (split-adjusted) | $3.23 | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history — Sum of 2 split-adjusted declared dividends with an ex-date in the 365 days to 2026-10-04, per current share. Ex-dates are not payment dates; special dividends are included. Not a declared annual rate. | |
div.ttm_yield | Dividend yield, last 12 months | 2.06% | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history and quote — Split-adjusted dividends with ex-dates in the trailing 365-day window divided by the packet price, on the same current-share basis. Price date follows the quote, latest price bar or packet-build day when unstamped. Not a forecast or declared annual rate. | |
earn.history.depth.2026-07-27.revenue_actual.comparison | Latest report · revenue vs estimate | Below estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported revenue ($15.38B) with the recorded estimate ($15.44B) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
earn.history.depth.2026-07-27.eps_actual.comparison | Latest report · EPS vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported EPS ($2.6300) with the recorded estimate ($2.5000) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
OURS — 2 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 85 of 100 · Exceptional · pillars 93 / 63 / 56 / 91 / 47 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.moonshot_change | MoonshotScore movement | 85 (stored snapshot Oct 4, 2026) → 85 (current publication computed Oct 5, 2026) (0) | OURS | Stock Expert AI current score publication and immutable score snapshots — The current score publication is not yet represented in the immutable snapshot archive. |
Fact-family notes
- Quarterly statement note. Source series as of 2026-06-30. USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow. Applies to Fact IDs:
fin.q_table.depth.2026-06-30.revenue_k,fin.q_table.depth.2026-06-30.rd_k,fin.q_table.depth.2026-06-30.sga_k,fin.q_table.depth.2026-06-30.operating_result_k,fin.q_table.depth.2026-03-31.revenue_k,fin.q_table.depth.2026-03-31.rd_k,fin.q_table.depth.2026-03-31.sga_k,fin.q_table.depth.2026-03-31.operating_result_k,fin.q_table.depth.2025-12-31.revenue_k,fin.q_table.depth.2025-12-31.rd_k,fin.q_table.depth.2025-12-31.sga_k,fin.q_table.depth.2025-12-31.operating_result_k,fin.q_table.depth.2025-09-30.revenue_k,fin.q_table.depth.2025-09-30.rd_k,fin.q_table.depth.2025-09-30.sga_k,fin.q_table.depth.2025-09-30.operating_result_k. - Earnings-history note. Source series as of 2026-07-27. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-07-27.revenue_actual,earn.history.depth.2026-07-27.revenue_estimated,earn.history.depth.2026-07-27.revenue_actual.comparison,earn.history.depth.2026-07-27.eps_actual.comparison,earn.history.depth.2026-07-27.eps_actual,earn.history.depth.2026-07-27.eps_estimated,earn.history.depth.2026-04-29.revenue_actual,earn.history.depth.2026-04-29.revenue_estimated,earn.history.depth.2026-04-29.eps_actual,earn.history.depth.2026-04-29.eps_estimated,earn.history.depth.2026-02-10.revenue_actual,earn.history.depth.2026-02-10.revenue_estimated,earn.history.depth.2026-02-10.eps_actual,earn.history.depth.2026-02-10.eps_estimated,earn.history.depth.2025-11-06.revenue_actual,earn.history.depth.2025-11-06.revenue_estimated,earn.history.depth.2025-11-06.eps_actual,earn.history.depth.2025-11-06.eps_estimated. - Cash-flow note. Source series as of 2026-06-30. USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway. Applies to Fact IDs:
fin.opcf.depth.2026-06-30.operating_cash_flow_m,fin.opcf.depth.2026-03-31.operating_cash_flow_m,fin.opcf.depth.2026-06-30.capex_m,fin.opcf.depth.2026-03-31.capex_m,fin.opcf.depth.2025-12-31.operating_cash_flow_m,fin.opcf.depth.2025-12-31.capex_m,fin.opcf.depth.2025-09-30.operating_cash_flow_m,fin.opcf.depth.2025-09-30.capex_m.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources used for research written 2026-09-12
Historical evidence preserved with this analysis. Current figures are listed separately above.
| Evidence | Captured value | Source date | Source type | Source |
|---|---|---|---|---|
| Business description | AstraZeneca PLC operates as a global biopharmaceutical leader, dedicated to the entire process of bringing prescription medicines to market, from their initial discovery and development through manufacturing and commercialization. The company's extensive portfolio of treatments, including prominent examples like Tagrisso, Farxiga, and Symbicort, addresses critical areas such as cardiovascular, renal, metabolic, and oncological conditions. Furthermore, it provides essential solutions for COVID-19 and various rare diseases, with products like Vaxzevria and Soliris. AstraZeneca engages with primary and specialty care physicians worldwide, facilitating distribution through a robust network of representatives and local offices across the United Kingdom, continental Europe, the Americas, Asia, Africa, and Australasia. The firm actively drives innovation through strategic collaborations, partnering with entities such as Neurimmune AG for the development and commercialization of NI006, BenevolentAI for systemic lupus erythematosus drug discovery, Lunit for AI-powered digital pathology risk assessment in NSCLC, and Absci Corporation for AI-driven oncology target identification. Founded in 1992, the company was initially known as Zeneca Group PLC, subsequently rebranding to AstraZeneca PLC in April 1999, and maintains its headquarters in Cambridge, United Kingdom. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) company profile |
| Revenue by segment | CVRM: $12.76B; Farxiga: $8.40B; Tagrisso: $7.25B; Rare Disease: $9.13B; Total Oncology: $23.70B | 2025-12-31 | FMP | Financial Modeling Prep (FMP) revenue segmentation, from the company's 10-K |
| Annual revenue and net result (USD millions) | Captured record · 5 entries
| 2025-12-31 | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements |
| Operating cash flow by quarter (USD millions) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements |
| Cash, investments and debt | Total debt: $32.20B; Liquidity basis: cash and short-term investments; Total liabilities: $65.39B; Cash and short-term investments: $4.96B; Cash and investments: $9.62B; Long-term investments: $4.66B; Long-term investments classification: unclassified Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet |
| Sector / industry (provider taxonomy) | Healthcare / Drug Manufacturers - General The company's SEC filings classify it under SIC 2834 — Pharmaceutical Preparations. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) company profile |
| Quarterly income statement (USD thousands) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements |
| Reported versus estimated, last 8 quarters | Captured record · 8 entries
| 2026-07-27 | FMP | Financial Modeling Prep (FMP) earnings |
| Management outlook — dated call excerpts | Captured record · 4 entries
Selected verbatim statements from the latest available call, dated by the transcript provider. Management expectations, not completed milestones or guarantees. Relative dates retain the speaker's wording. | 2026-07-27 | OFFICIAL | Company earnings call, transcript via Financial Modeling Prep (FMP) |
| Cash and investment components | Total basis: cash short and long-term investments; Total: $9.62B; Cash and short-term investments: $4.96B; Long-term investments: $4.66B; Long-term investments classification: unclassified Sums the balance sheet's cash and short-term investments with its long-term investments.; The long-term investment field does not establish marketability; the sum is not a measure of available liquidity.; These provider fields do not establish investment access restrictions or explain differences from third-party cash figures. | 2026-06-30 | COMPUTED | Computed from the balance sheet |
| Cash and short-term investments over time (USD millions) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's quarterly balance sheets |
| Cash against market value | As of: 2026-06-30; Cash basis: cash and short-term investments; Net cash: -$27.24B; Total debt: $32.20B; Cash and investments: $4.96B Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. Cash is the latest reported cash and short-term investment balance; long-term investments are excluded. Market capitalization is the latest provider value.; The reported balance does not establish unrestricted availability or liquidation value.; The two are measured on different dates — the balance sheet is a quarter-end, the market cap is a recent close.; Debt is total debt as reported, including operating lease liabilities where the filer includes them. | 2026-06-30 | COMPUTED | Computed from the balance sheet and the latest market capitalization |
| Trailing twelve-month ratio set | Quick ratio: 0.67; Current ratio: 0.89; Debt to equity: 0.64; Net margin: 17%; Gross margin: 79.3%; Operating margin: 22.7%; Return on assets: 9%; Return on equity: 21.7% Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. A ratio our provider could not compute is absent rather than shown as zero. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm |
| Distress and quality screens | Altman Z-score: 3.33; Piotroski F-score: 8 Altman Z below 1.8 is the conventional distress zone. For a company holding large cash against negative retained earnings the score mostly reflects the retained-earnings term. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) financial scores |
| Next earnings report | Date: 2026-10-30; EPS estimate: $2.62 per share; Revenue estimate: $16.06B The date is our provider's estimate until the company confirms it. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) earnings calendar |
| Analyst revenue and earnings estimates (average) | Captured record · 4 entries
| 2026-09-12 | FMP | Financial Modeling Prep (FMP) analyst estimates |
Data provided for informational purposes only.
ETFs that hold AZN
Funds in our ETF coverage that list AZN among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| Thornburg International Equity ETF (TXUE) | 3.36% |